Determination of Pt-DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

International Journal of Mass Spectrometry

Volumn 307, Issue 1-3, 2011, Pages 70-78

  Zayed, Aref ^a   Shoeib, Tamer ^a,b   Taylor, Sarah E ^a   Jones, George D D ^c   Thomas, Anne L ^d   Wood, Joanna P ^d   Reid, Helen J ^a   Sharp, Barry L ^a  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b BRITISH UNIVERSITY IN EGYPT   (Egypt)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cisplatin; FOLFOX; ICP MS; Oxaliplatin; Pt DNA adducts; Sub cellular fractionation

Indexed keywords

EID: 80052966564     PISSN: 13873806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijms.2010.11.012     Document Type: Article

References (85)

1. S.E. Sherman, and S.J. Lippard Structural aspects of platinum anticancer drug interactions with DNA Chem. Rev. 87 1987 1153 1181
2. S. Culine Chimiothérapie des tumeurs germinales métastatiques du testicule de bon pronostic Oncologie 10 2008 446 450 (Pubitemid 351938269)
3. L. Ta Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding Neurotoxicology 27 2006 992 1002 (Pubitemid 44838955)
4. P.J. O'Dwyer, J.P. Stevenson, and S.W. Johnson Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs B. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Wiley-VCH 29 70
5. M.H. Hanigan, and P. Devarajan Cisplatin nephrotoxicity: molecular mechanisms Cancer Ther. 1 2003 47 61
6. E.R. Jamieson, and S.J. Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99 1999 2467 2498
7. M. Kartalou, and J.M. Essigmann Mechanisms of resistance to cisplatin Mutat. Res. Fundam. Mol. Mech. Mugag. 478 2001 23 43 (Pubitemid 32530848)
8. V. Brabec, and J. Kasparkova Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs Drug Resist. Updat. 8 2005 131 146 (Pubitemid 41267064)
9. P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L. Elbling, M. Micksche, B. Keppler, and W. Berger Resistance against novel anticancer metal compounds: differences and similarities Drug Resist. Updat. 11 2008 1 16
10. P. Borst, S. Rottenberg, and J. Jonkers How do real tumors become resistant to cisplatin? Cell Cycle 7 2008 1353 1359 (Pubitemid 351872573)
11. L.E. Ta, L. Espeset, J. Podratz, and A.J. Windebank Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding NeuroToxicology 27 2006 992 1002 (Pubitemid 44838955)
12. S. Arnould, I. Hennebelle, P. Canal, R. Bugat, and S. Guichard Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur. J. Cancer 39 2003 112 119 (Pubitemid 36005433)
13. G.M. Almeida, T.L. Duarte, W.P. Steward, and G.D.D. Jones Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay DNA Repair 5 2006 219 225 (Pubitemid 43069522)
14. S.G. Chaney, S.L. Campbell, B. Temple, E. Bassett, Y. Wu, and M. Faldu Protein interactions with platinum-DNA adducts: from structure to function J. Inorg. Biochem. 98 2004 1551 1559 (Pubitemid 39349180)
15. R. Mandal, M.B. Sawyer, and X. Li Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses Rapid Commun. Mass Spectrom. 20 2006 2533 2538 (Pubitemid 44320206)
16. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol. Cancer. Ther. 1 2002 227 235
17. S.G. Chaney, S.L. Campbell, E. Bassett, and Y. Wu Recognition and processing of cisplatin- and oxaliplatin-DNA adducts Crit. Rev. Oncol. 53 2005 3 11 (Pubitemid 39656106)
18. Y. Jung, and S.J. Lippard Direct cellular responses to platinum-induced DNA damage Chem. Rev. 107 2007 1387 1407 (Pubitemid 46864967)
19. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320 (Pubitemid 41130944)
20. E. Björn, Y. Nygren, T.T. Thi Nhu Nguyen, C. Ericson, M. Nöjd, and P. Naredi Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry Anal. Biochem. 363 2007 135 142 (Pubitemid 46348979)
21. E. Volckova, L.P. Dudones, and R.N. Bose HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: implications of dominant platinum-thiol binding to its anticancer action Pharm. Res. 19 2002 124 131 (Pubitemid 34165396)
22. C. Lottner, R. Knuechel, G. Bernhardt, and H. Brunner Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells Cancer Lett. 215 2004 167 177 (Pubitemid 39370034)
23. P. Marqués-Gallego, G.V. Kalayda, U. Jaehde, H.d. Dulk, J. Brouwer, and J. Reedijk Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands J. Inorg. Biochem. 103 2009 791 796
24. J.M. Woynarowski, W.G. Chapman, C. Napier, M.C.S. Herzig, and P. Juniewicz Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol. Pharmacol. 54 1998 770 777 (Pubitemid 28523169)
25. J. Kozelka Molecular origin of the sequence-dependent kinetics of reactions between cisplatin derivatives and DNA Inorg. Chim. Acta 362 2009 651 668
26. F. Arnesano, and G. Natile Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA Coord. Chem. Rev. 253 2009 2070 2081
27. D.V. Deubel Factors governing the kinetic competition of nitrogen and sulfur ligands in cisplatin binding to biological targets J. Am. Chem. Soc. 126 2004 5999 6004 (Pubitemid 38637967)
28. Y. Kasherman, S. Sturup, and D. Gibson Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts J. Med. Chem. 52 2009 4319 4328
29. J. Reedijk Improved understanding in platinium antitumour chemistry Chem. Commun. 7 1996 801 806 (Pubitemid 26119541)
30. Z. Guo, and P.J. Sadler Metals in medicine Angew. Chem. Int. Ed. Engl. 38 1999 1512 1531
31. S.M. Cohen, and S.J. Lippard Cisplatin: from DNA damage to cancer chemotherapy Prog. Nucleic Acid Res. Mol. Biol. 67 2001 93 130 (Pubitemid 33804642)
32. T.W. Hambley Platinum binding to DNA: structural controls and consequences J. Chem. Soc., Dalton Trans. 19 2001 2711 2718 (Pubitemid 35151846)
33. P. Ilinski, B. Lai, Z. Cai, W. Yun, D. Legnini, T. Talarico, M. Cholewa, L.K. Webster, G.B. Deacon, S. Rainone, D.R. Phillips, and A.P. Stampfl The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe Cancer Res. 63 2003 1776 1779 (Pubitemid 36460837)
34. A.E. Egger, C. Rappel, M.A. Jakupec, C.G. Hartinger, P. Heffeter, and B.K. Keppler Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells J. Anal. At. Spectrom. 24 2009 51 61
35. R.M. Xing Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin J. Inorg. Biochem. 103 2009 1039 1044
36. D. Garmann, A. Warnecke, G.V. Kalayda, F. Kratz, and U. Jaehde Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells J. Control. Release 131 2008 100 106
37. M. Salerno Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells J. Biol. Inorg. Chem. 14 2009 123 132
38. A. Ghezzi, M. Aceto, C. Cassino, E. Gabano, and D. Osella Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS) J. Inorg. Biochem. 98 2004 73 78 (Pubitemid 37495012)
39. P.A. Andrews, and S.B. Howell Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance Cancer Cell 2 1990 35 43 (Pubitemid 20218552)
40. J. Holford, P.J. Beale, F.E. Boxall, S.Y. Sharp, and L.R. Kelland Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines Eur. J. Cancer 36 2000 1984 1990
41. Z. Chen, M. Mutoh, T. Sumizawa, T. Furukawa, M. Haraguchi, A. Tani, N. Saijo, T. Kondo, and S. Akiyama An active efflux system for heavy metals in cisplatin-resistant human KB Carcinoma cells Exp. Cell Res. 240 1998 312 320 (Pubitemid 28371112)
42. M. Mishima, G. Samimi, A. Kondo, X. Lin, and S.B. Howell The cellular pharmacology of oxaliplatin resistance Eur. J. Cancer 38 2002 1405 1412 (Pubitemid 34686853)
43. K.R. Grigoryan, M.G. Azanuryan, N.A. Bagramyan, L.G. Grvorkyan, and S.A. Markaryan Spectroscopic determination of binding between human serum albumin and a platinum(II) dimethylsulfoxide complex J. Appl. Spectrosc. 75 2008 593 596
44. I. Takahashi, T. Ohnuma, S. Kavy, S. Bhardwaj, and J.F. Holland Interaction of human serum albumin with anticancer agents in vitro Br. J. Cancer 41 1980 602 608 (Pubitemid 10125492)
45. N. Ohta, D. Chen, S. Ito, and T. Futo Effect of trans- diamminedichloroplatinum(II) on human serum albumin: conformational changes through partial disulfide bond cleavage Int. J. Pharm. 118 1995 85 93
46. A.I. Ivanov, J. Christodoulou, J.A. Parkinson, K.J. Barnham, A. Tucker, J. Woodrow, and P.J. Sadler Cisplatin binding sites on human albumin J. Biol. Chem. 273 1998 14721 14730 (Pubitemid 28272756)
47. B.P. Espósito, and R. Najjar Interactions of antitumoral platinum-group metallodrugs with albumin Coord. Chem. Rev. 232 2002 137 149
48. A. Warnecke, I. Fichtner, D. Garmann, U. Jaehde, and F. Kratz Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs Bioconjug. Chem. 15 2004 1349 1359 (Pubitemid 39552025)
49. V. Cepeda, M.A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J.M. Perez Biochemical mechanisms of cisplatin cytotoxicity Anticancer Agents Med. Chem. 7 2007 3 18 (Pubitemid 46062402)
50. C.L. Litterst, and V.G. Schweitzer Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: possible role in nephrotoxicity Res. Commun. Chem. Pathol. Pharmacol. 61 1988 35 48
51. S. Akiyama, Z.S. Chen, T. Sumizawa, and T. Furukawa Resistance to cisplatin Anticancer Drug Des. 14 1999 143 151 (Pubitemid 29292311)
52. V. Brabec, and J. Kasparkova Molecular aspects of resistance to antitumor platinum drugs Drug Resist. Updat. 5 2002 147 161 (Pubitemid 35033806)
53. T. Ishikawa, and F. Ali-Osman Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance J. Biol. Chem. 268 1993 20116 20125 (Pubitemid 23278910)
54. A.K. Godwin, A. Meister, P.J. O'Dwyer, C.S. Huang, T.C. Hamilton, and M.E. Anderson High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc. Natl. Acad. Sci. U S A 89 1992 3070 3074
55. P. Mistry, L.R. Kelland, G. Abel, S. Sidhar, and K.R. Harrap The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines Br. J. Cancer 64 1991 215 220
56. T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, and A. de Gramont Multicenter international study of oxaliplatin/5-fluorouracil/ leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators, oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N. Engl. J. Med. 350 2004 2343 2351
57. A. Molassiotis, P. Fernadez-Ortega, D. Pud, G. Ozden, J.A. Scott, V. Panteli, A. Margulies, M. Browall, M. Magri, S. Selvekerova, E. Madsen, L. Milovics, I. Bruyns, G. Gudmundsdottir, S. Hummerston, A.M. Ahmad, N. Platin, N. Kearney, and E. Patiraki Use of complementary and alternative medicine in cancer patients: a European survey Ann. Oncol. 16 2005 655 663 (Pubitemid 40613334)
58. M. Suzuki, M. Endo, F. Shinohara, S. Echigo, and H. Rikiishi Differential apoptotic response of human cancer cells to organoselenium compounds Cancer Chemother. Pharmacol. 66 2010 475-484; 484
59. M.P. Rayman Selenium in cancer prevention: a review of the evidence and mechanism of action Proc. Nutr. Soc. 64 2005 527 542 (Pubitemid 41705454)
60. Y. Hu, Y. Chen, Y. Zhang, M. Zhou, X. Song, B. Zhang, L. Luo, P. Xu, Y. Zhao, Y. Zhao, and G. Cheng The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients Biol. Trace Elem. Res. 56 1997 331 341 (Pubitemid 27255781)
61. S.K. Mauldin, G. Gibbons, S.D. Wyrick, and S.G. Chaney Intracellular biotransformation of platinum compounds with the 1, 2-diaminocyclohexane carrier ligand in the L1210 cell line Cancer Res. 48 1988 5136 5144
62. M.E. Leibbrandt, G.H. Wolfgang, A.L. Metz, A.A. Ozobia, and J.R. Haskins Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells Kidney Int. 48 1995 761 770
63. R.P. Sharma, and I.R. Edwards cis-Platinum: subcellular distribution and binding to cytosolic ligands Biochem. Pharmacol. 32 1983 2665 2669 (Pubitemid 13009414)
64. B.A. Teicher, S.A. Holden, J.L. Jacobs, M.J. Abrams, and A.G. Jones Intracellular distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and resistant human squamous carcinoma cell lines Biochem. Pharmacol. 35 1986 3365 3369 (Pubitemid 16001448)
65. D. Gibson The mechanism of action of platinum anticancer agents - what do we really know about it? Dalton Trans. 2009 10681
66. Z. Yang, X.D. Hou, and B.T. Jones Determination of platinum in clinical samples Appl. Spectrosc. Rev. 37 2002 88
67. G.J. Veal, J. Errington, M.J. Tilby, A.D. Pearson, A.B. Foot, H. McDowell, C. Ellershaw, B. Pizer, G.M. Nowell, D.G. Pearson, A.V. Boddy UKCCSG Pharmacology Working Group Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours Br. J. Cancer 96 2007 725 731 (Pubitemid 46376616)
68. B.W. Cooper, G.J. Veal, T. Radivoyevitch, M.J. Tilby, H.J. Meyerson, H.M. Lazarus, O.N. Koc, R.J. Creger, G. Pearson, G.M. Nowell, D. Gosky, S.T. Ingalls, C.L. Hoppel, and S.L. Gerson A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia Clin. Cancer Res. 10 2004 6830 6839 (Pubitemid 39383031)
69. D. Pozebon, V.L. Dressler, A. Matusch, and J.S. Becker Monitoring of platinum in a single hair by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) after cisplatin treatment for cancer Int. J. Mass Spectrom. 272 2008 57 62
70. J.G. Morrison, P. White, S. McDougall, J.W. Firth, S.G. Woolfrey, M.A. Graham, and D. Greenslade Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin J. Pharmaceut. Biomed. 24 2000 1 10
71. S. Dawood, and B. Leyland-Jones Pharmacology and pharmacogenetics of chemotherapeutic agents Cancer Invest. 27 2009 482 488
72. A. Abdolzade-Bavil, S. Hayes, L. Goretzki, M. Kroger, J. Anders, and R. Hendriks Convenient and versatile subcellular extraction procedure, that facilitates classical protein expression profiling and functional protein analysis Proteomics 4 2004 1397 1405 (Pubitemid 38648028)
73. G.M. Almeida, T.L. Duarte, P.B. Farmer, W.P. Steward, and G.D.D. Jones Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing Int. J. Cancer 122 2008 1810 1819 (Pubitemid 351413428)
74. K. Yamada, N. Kato, A. Takagi, M. Koi, and H. Hemmi One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes Anal. Bioanal Chem. 382 2005 1702 1707 (Pubitemid 41090481)
75. S. Kerr, Enhancing nucleic acid detection using inductively coupled plasma mass spectrometry, by means of metal and nano-particle labelling, PhD Thesis, Loughborough University, 2008.
76. I. Rodushkin, E. Engstrom, A. Stenberg, and D.C. Baxter Determination of low-abundance elements at ultra-trace levels in urine and serum by inductively coupled plasma-sector field mass spectrometry Anal. Bioanal. Chem. 380 2004 247 257
77. S. Hann, G. Koellensperger, K. Kanitsar, G. Stingeder, M. Brunner, B. Erovic, M. Muller, and C. Reiter Platinum determination by inductively coupled plasma-sector field mass spectrometry (ICP-SFMS) in different matrices relevant to human biomonitoring Anal. Bioanal Chem. 376 2003 198 204 (Pubitemid 40878052)
78. E. Brouwers, M. Tibben, H. Rosing, J. Schellens, and J. Beijnen The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research Mass Spectrom. Rev. 27 2008 67 100 (Pubitemid 351315896)
79. M.J.P. Welters, M. Maliepaard, A.J. Jacobs-Bergmans, R.A. Baan, J.H.M. Schellens, J. Ma, W.J.F. Van der Vijgh, B.J.M. Braakhuis, and A.M.J. Fichtinger-Schepman Improved 3 2P-postlabelling assay for the quantification of the major platinum-DNA adducts Carcinogenesis 18 1997 1774
80. G. Weber, J. Messerschmidt, A.C. Pieck, A.M. Junker, A. Wehmeier, and U. Jaehde Ultratrace voltammetric determination of DNA-bound platinum in patients after administration of oxaliplatin Anal. Bioanal. Chem. 380 2004 58
81. E.E.M. Brouwers, M. Tibben, D. Pluim, H. Rosing, H. Boot, A. Cats, J.H.M. Schellens, and J.H. Beijnen Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin Anal. Bioanal. Chem. 391 2008 577 585
82. C.R. Centerwall, K.A. Tacka, D.J. Kerwood, J. Goodisman, B.B. Toms, R.L. Dubowy, and J.C. Dabrowiak Modification and uptake of a cisplatin carbonato complex by jurkat cells Mol. Pharmacol. 70 2006 348 355
83. J. Reedijk Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev. 99 1999 2499 2510
84. D. Theile, S. Grebhardt, W.E. Haefeli, and J. Weiss Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy Biochem. Pharmacol. 78 2009 1366 1373
85. ® Subcellular Proteome Extraction Kit. http://www.merck-chemicals.co.uk/life-science-research/ proteoextract-subcellular-proteome-extraction-kit/EMD-BIO-539790/p-xdCb. s1ORVMAAAEjpxp9.zLX, 2010 (accessed 07.11.2010).